Sorry mate, you misunderstood what I said.
Perhaps my fault as I had just returned from winter camping in the back country within Canada and was tired, and a little intoxicated (and angry tbh).
I've held these shares for years, dropped 20k (with an average buy price of over 20 cents) in the company based on the pre-clinical science and the public statement that future financing would be acquired from Noxopharm without share dilution.
As for the 10% salary bump... No company should be giving Execs pay raises when it doesn't generate an income or have a marketable product.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
26.0¢ |
Change
0.025(10.6%) |
Mkt cap ! $54.83M | |||
| Open | High | Low | Value | Volume |
| 23.5¢ | 26.5¢ | 23.5¢ | $352.7K | 1.440M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3600 | 24.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 26.0¢ | 4499 | 1 |
View Market Depth
| Last trade - 16.10pm 18/06/2025 (20 minute delay) ? |
| NYR (ASX) Chart |